Abstract
Learning objectives Radium-223 is an alpha emitter, licensed in 2013 for treatment of symptomatic bone metastases in metastatic castration resistant prostate cancer. The treatment consists of 6 intravenous administrations and ongoing patient management before, during and after treatment. In our institution, this service is led by the nuclear medicine department The ALSYMPCA trial, published in 2013, demonstrated improved overall survival (14.9 vs 11.3 months) and prolonged time to first symptomatic skeletal event (15.6 vs 9 months) for patients administered Radium-223 vs placebo Imaging plays a key role in the selection criteria and response assessment for this new therapeutic modality. We present an educational review of the spectrum of multimodality imaging techniques employed for pretherapeutic assessment and also for therapeutic response assessment
Highlights
Learning objectives Radium-223 is an alpha emitter, licensed in 2013 for treatment of symptomatic bone metastases in metastatic castration resistant prostate cancer
The treatment consists of 6 intravenous administrations and ongoing patient management before, during and after treatment. This service is led by the nuclear medicine department
We present an educational review of the spectrum of multimodality imaging techniques employed for pretherapeutic assessment and for therapeutic response assessment the future
Summary
Learning objectives Radium-223 is an alpha emitter, licensed in 2013 for treatment of symptomatic bone metastases in metastatic castration resistant prostate cancer. Patient selection and treatment response assessment in radium-223 therapy From International Cancer Imaging Society Meeting and 15th Annual Teaching Course (ICIS 2015) London, UK. The treatment consists of 6 intravenous administrations and ongoing patient management before, during and after treatment.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
